Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Leases (2019 - 2025)

Enanta Pharmaceuticals filings provide 7 years of Leases readings, the most recent being $37.0 million for Q4 2025.

  • On a quarterly basis, Leases fell 6.73% to $37.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.0 million, a 6.73% decrease, with the full-year FY2025 number at $37.5 million, down 7.65% from a year prior.
  • Leases hit $37.0 million in Q4 2025 for Enanta Pharmaceuticals, down from $37.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $41.2 million in Q2 2024 to a low of $4.7 million in Q3 2021.
  • Median Leases over the past 5 years was $23.8 million (2022), compared with a mean of $26.1 million.
  • Biggest five-year swings in Leases: plummeted 32.89% in 2021 and later soared 400.42% in 2022.
  • Enanta Pharmaceuticals' Leases stood at $18.8 million in 2021, then increased by 24.99% to $23.5 million in 2022, then decreased by 9.33% to $21.3 million in 2023, then surged by 85.88% to $39.7 million in 2024, then decreased by 6.73% to $37.0 million in 2025.
  • The last three reported values for Leases were $37.0 million (Q4 2025), $37.5 million (Q3 2025), and $38.2 million (Q2 2025) per Business Quant data.